33 research outputs found
Chitosan-coated alginate micro-particles delivery of active principles through conventional pelleted food - A study in Tilapia (Oreochromis niloticus)
The search for alternatives to antibiotics in aquaculture has focused on the use of vaccines for immune-prophylaxis. The purpose of this study was to examine the feasibility and characteristics of chitosan-alginate microparticles for the oral delivery of immune-prophylactics to finfish. The microparticles, which incorporate fluorescent-labelled lysozyme, were produced by spray-drying method; their structural properties and uptake from the gastrointestinal tract of Tilapia (Oreochromis niloticus) were assessed by microscopy. The main findings show that the microparticles are able to retain their content in an acidic environment and to release it later in slightly alkaline conditions such as those found in the intestines. Moreover, both the microencapsulation procedure and the biopolymers used have no deleterious impact on the lysozyme lytic activity, which is maintained after the protein has been released from the microparticles. Administered in vivo in Tilapia by medicated food, the microparticles transit unaffected through the stomach, and reach the anterior intestines, in particular the villum sectum and the basal lamina of epithelial cells, 2 and 4 h after feeding. Overall, the evidence obtained here supports the potential of these chitosan-alginate microparticles as agents for oral immune-prophylaxis in the management of fish diseases
Leveraging Big Data to Preserve the Mississippi River Valley Alluvial Aquifer: A Blueprint for the National Center for Alluvial Aquifer Research
The challenge of a depleting Mississippi River Valley Alluvial Aquifer (MRVAA) requires reducing groundwater withdrawal for irrigation, increasing aquifer recharge, and protecting water quality for sustainable water use. To meet the challenge, the National Center for Alluvial Aquifer Research (NCAAR) is oriented towards producing scientific work aimed at improving irrigation methods and scheduling, employing alternative water sources, and improving crop management and field practices to increase water use efficiency across the region. Big data is key for NCAAR success. Its scientists use big data for research in the form of various soil, weather, geospatial, and water monitoring and management devices to collect agronomic or hydrogeologic data. They also produce, process, and analyze big data which are converted to scientific publications and farm management recommendations via technology transfer. Similarly, decision tools that would help producers leverage the wealth of data they generate from their operations will also be developed and made available to them. This article outlines some of the many ways big data is intertwined with NCAARâs mission
Characterizing Lower Extremity Lymphedema and Lipedema with Cutaneous Ultrasonography and an Objective Computer-Assisted Measurement of Dermal Echogenicity
Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin.
OBJECTIVES: To investigate the relationship between the improved stability of an anticancer drug-lipiodol emulsion and pharmacokinetic (PK) profile for transarterial chemoembolisation (TACE) of hepatocellular carcinoma (HCC).
METHODS: The stability of four doxorubicin- or idarubicin-lipiodol emulsions was evaluated over 7 days. PK and clinical data were recorded after TACE with the most stable emulsion in eight unresectable HCC patients, after institutional review board approval.
RESULTS: The most stable emulsion was the one that combined idarubicin and lipiodol (1:2 v:v). At 7 days, the percentages of aqueous, persisting emulsion and oily phases were 50-0-50, 33-0-67, 31-39-30, and 10-90-0 for the doxorubicin-lipiodol (1:1 v:v), doxorubicin-lipiodol (1:2 v:v), idarubicin-lipiodol (1:1 v:v), and the idarubicin-lipiodol (1:2 v:v) emulsion, respectively. After TACE, mean idarubicin Cmax and AUC0-24h were 12.5â±â9.4 ng/mL and 52â±â16 ng/mL*h. Within 24 h after injection, 40% of the idarubicin was in the liver, either in vessels, tumours, or hepatocytes. During the 2 months after TACE, no clinical grade >3 adverse events occurred. One complete response, five partial responses, one stabilisation, and one progression were observed at 2 months.
CONCLUSION: This study showed a promising and favourable PK and safety profile for the idarubicin-lipiodol (1:2 v:v) emulsion for TACE.
KEY POINTS: âą Transarterial chemoembolisation (TACE) regimens that improve survival in hepatocellular carcinoma are needed. âą Improved emulsion stability for TACE resulted in a favourable pharmacokinetic profile. âą Preliminary safety and efficacy data for the idarubicin-lipiodol emulsion for TACE were encouraging
Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin
To investigate the relationship between the improved stability of an anticancer drug-lipiodol emulsion and pharmacokinetic (PK) profile for transarterial chemoembolisation (TACE) of hepatocellular carcinoma (HCC). The stability of four doxorubicin- or idarubicin-lipiodol emulsions was evaluated over 7 days. PK and clinical data were recorded after TACE with the most stable emulsion in eight unresectable HCC patients, after institutional review board approval. The most stable emulsion was the one that combined idarubicin and lipiodol (1:2 v:v). At 7 days, the percentages of aqueous, persisting emulsion and oily phases were 50-0-50, 33-0-67, 31-39-30, and 10-90-0 for the doxorubicin-lipiodol (1:1 v:v), doxorubicin-lipiodol (1:2 v:v), idarubicin-lipiodol (1:1 v:v), and the idarubicin-lipiodol (1:2 v:v) emulsion, respectively. After TACE, mean idarubicin C-max and AUC(0-24h) were 12.5 +/- 9.4 ng/mL and 52 +/- 16 ng/mL*h. Within 24 h after injection, 40 % of the idarubicin was in the liver, either in vessels, tumours, or hepatocytes. During the 2 months after TACE, no clinical grade > 3 adverse events occurred. One complete response, five partial responses, one stabilisation, and one progression were observed at 2 months. This study showed a promising and favourable PK and safety profile for the idarubicin-lipiodol (1:2 v:v) emulsion for TACE. aEuro cent Transarterial chemoembolisation (TACE) regimens that improve survival in hepatocellular carcinoma are needed. aEuro cent Improved emulsion stability for TACE resulted in a favourable pharmacokinetic profile. aEuro cent Preliminary safety and efficacy data for the idarubicin-lipiodol emulsion for TACE were encouraging
Simultaneous trans-hepatic portal and hepatic vein embolization before major hepatectomy: the liver venous deprivation technique.
To assess technical feasibility, safety, and efficacy of the liver venous deprivation (LVD) technique that combines both portal and hepatic vein embolization during the same procedure for liver preparation before major hepatectomy.
Seven patients (mean age:63.6y[42-77y]) underwent trans-hepatic LVD for liver metastases (nâ=â2), hepatocellular carcinoma (nâ=â1), intrahepatic cholangiocarcinoma (nâ=â3) and Klatskin tumour (nâ=â1). Assessment of future remnant liver (FRL) volume, liver enzymes and histology was performed.
Technical success was 100 %. No complication occurred before surgery. Resection was performed in 6/7 patients. CT-scan revealed hepatic congestion in the venous-deprived area (6/7 patients). A mean of 3 days (range: 1-8 days) after LVD, transaminases increased (AST: from 42â±â24U/L to 103â±â118U/L, ALT: from 45â±â25U/L to 163â±â205U/L). Twenty-three days (range: 13-30 days) after LVD, FRL increased from 28.2 % (range: 22.4-33.3 %) to 40.9 % (range: 33.6-59.3 %). During the first 7 days, venous-deprived liver volume increased (+13.4 %) probably reflecting vascular congestion, whereas it strongly decreased (-21.3 %) at 3-4 weeks. Histology (embolized lobe) revealed sinusoidal dilatation, hepatocyte necrosis and important atrophy in all patients.
Trans-hepatic LVD technique is feasible, well tolerated and provides fast and important hypertrophy of the FRL. This new technique needs to be further evaluated and compared to portal vein embolization.
âą Twenty-three days after LVD, FRL increased from 28.2Â % (range:22.4-33.3Â %) to 40.9Â % (range:33.6-59.3Â %) âą During the first 7Â days, venous-deprived liver volume increased (+13.4Â %) âą Venous-deprived liver volume strongly decreased (mean atrophy:229Â cc; -21.3Â %) at 3-4 weeks âą Histology of venous-deprived liver revealed sinusoidal dilatation, hepatocyte necrosis and important atrophy
Simultaneous trans-hepatic portal and hepatic vein embolization before major hepatectomy: the liver venous deprivation technique
To assess technical feasibility, safety, and efficacy of the liver venous deprivation (LVD) technique that combines both portal and hepatic vein embolization during the same procedure for liver preparation before major hepatectomy. Seven patients (mean age:63.6y[42-77y]) underwent trans-hepatic LVD for liver metastases (n = 2), hepatocellular carcinoma (n = 1), intrahepatic cholangiocarcinoma (n = 3) and Klatskin tumour (n = 1). Assessment of future remnant liver (FRL) volume, liver enzymes and histology was performed. Technical success was 100 %. No complication occurred before surgery. Resection was performed in 6/7 patients. CT-scan revealed hepatic congestion in the venous-deprived area (6/7 patients). A mean of 3 days (range: 1-8 days) after LVD, transaminases increased (AST: from 42 +/- 24U/L to 103 +/- 118U/L, ALT: from 45 +/- 25U/L to 163 +/- 205U/L). Twenty-three days (range: 13-30 days) after LVD, FRL increased from 28.2 % (range: 22.4-33.3 %) to 40.9 % (range: 33.6-59.3 %). During the first 7 days, venous-deprived liver volume increased (+13.4 %) probably reflecting vascular congestion, whereas it strongly decreased (-21.3 %) at 3-4 weeks. Histology (embolized lobe) revealed sinusoidal dilatation, hepatocyte necrosis and important atrophy in all patients. Trans-hepatic LVD technique is feasible, well tolerated and provides fast and important hypertrophy of the FRL. This new technique needs to be further evaluated and compared to portal vein embolization. aEuro cent Twenty-three days after LVD, FRL increased from 28.2 % (range:22.4-33.3 %) to 40.9 % (range:33.6-59.3 %) aEuro cent During the first 7 days, venous-deprived liver volume increased (+13.4 %) aEuro cent Venous-deprived liver volume strongly decreased (mean atrophy:229 cc; -21.3 %) at 3-4 weeks aEuro cent Histology of venous-deprived liver revealed sinusoidal dilatation, hepatocyte necrosis and important atrophy